Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse
Open Access
- 2 February 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 786451
Abstract
Background: Despite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), patients with multiple myeloma (MM) invariably relapse. Molecular residual disease (MRD)-negativity post-AHCT has emerged as an important prognostic marker predicting the duration of remission. Current techniques for MRD assessment involve bone marrow (BM) aspirate sampling, which is invasive, subject to sample variability and is limited by spatial heterogeneity. We compared the performance of a non-invasive, circulating tumor DNA (ctDNA)-based MRD assay with multiparameter flow cytometry (MFC) of marrow aspirate to predict relapse in AHCT recipients with MM. Methods: MRD assessment using ctDNA was retrospectively analyzed on 80 plasma samples collected at different time points from 28 patients, post-AHCT. MFC was used to assess MRD from BM biopsy. Individual archived BM aspirate slides or formalin-fixed paraffin-embedded slides from the time of MM diagnosis and matched blood were used to assess MRD at 3 months, post-AHCT, using a personalized, tumor-informed ctDNA assay. Results: ctDNA was detectable in 70.8% (17/24) of pre-AHCT patients and 53.6% (15/28) of post-AHCT patients (3-month time point). Of the 15 post-AHCT ctDNA-positive patients, 14 relapsed on follow-up. The median PFS for ctDNA-positive patients was 31 months, and that for ctDNA-negative patients was 84 months (HR: 5.6; 95%CI: 1.8-17;p=0.0003). No significant difference in PFS was observed in patients stratified by MFC-based MRD status (HR 1.2; 95%CI: 0.3-3.4;p=0.73). The positive predictive value for ctDNA was also significantly higher than MFC (93.3% vs. 68.4%). Conclusions: This study demonstrates tumor-informed ctDNA analysis is strongly predictive of MM relapse.Keywords
This publication has 22 references indexed in Scilit:
- Novel biomarkers in multiple myelomaTranslational Research, 2018
- Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrowBlood Advances, 2018
- Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple MyelomaSeminars in Hematology, 2018
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencingNature Communications, 2017
- In situ click chemistry generation of cyclooxygenase-2 inhibitorsNature Communications, 2017
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myelomaLeukemia, 2017
- Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysisBone Marrow Transplantation, 2016
- Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on SurvivalClinical Lymphoma Myeloma and Leukemia, 2016
- Multiple Myeloma, Version 2.2016Journal of the National Comprehensive Cancer Network, 2015
- Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma PatientsClinical Lymphoma Myeloma and Leukemia, 2014